KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population

Human Immunology

Volumn 73, Issue 9, 2012, Pages 927-931

  Wiśniewski, Andrzej ^a   Jankowska, Renata ^b   Passowicz Muszyńska, Ewa ^b   Wiśniewska, Elzbieta ^b   Majorczyk, Edyta ^a,c   Nowak, Izabela ^a   Frydecka, Irena ^a,b   Kuśnierczyk, Piotr ^a,d  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c OPOLE UNIVERSITY OF TECHNOLOGY   (Poland)

^d REGIONAL SPECIALIST HOSPITAL   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENOTYPE; HOMOZYGOTE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLAND; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HLA-C ANTIGENS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLAND; RECEPTORS, KIR; RECEPTORS, KIR2DL2; RISK FACTORS; TREATMENT OUTCOME;

EID: 84865395817     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.07.323     Document Type: Article

References (27)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002 CA. Cancer J Clin 2002, 52:23-47.
2. #211980. Lung cancer. Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/omim.
3. Bubenik J. MHC class I down-regulation: tumour escape from immune surveillance? (review). Int J Oncol 2004, 25:487-491.
4. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005, 5:201-214.
5. Kuśnierczyk P. Sensing the self: Structure, genetics, biological function and possible disease associations of KIR genes and molecules. Leading-Edge Immunology Research 2006, 95-125. Nova Science Publishers, Inc., New York. B.A. Veskler (Ed.).
6. Al Omar S., Middleton D., Marshall E., Porter D., Xinarianos G., Raji O. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol 2010, 71:976-981.
7. Nowak I., Majorczyk E., Wiśniewski A., Pawlik A., Magott-Procelewska M., Passowicz-Muszyńska E., et al. Does the KIR2DS5 gene protect from some human diseases?. PLoS ONE 2010, 5(8):e12381.
8. World Health Organization. Histological Typing of Lung Tumours. 2nd Edn, Geneva, World Health Organization, 1981.
9. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, in Collaboration with Sobin LH and Pathologists from 14 Countries. World Health Organization International Histological Classification of Tumors. Histological Typing of Lung and Pleural Tumours, 3rd ed. Berlin: Springer-Verlag, 1999.
10. Brambilla E., Travis W.D., Colby T.V., Corrin B., Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001, 18:1059-1068.
11. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136(1):260-271.
12. Łuszczek W., Mańczak M., Cisło M., Nockowski P., Wiśniewski A., Jasek M. Gene for the activating natural killer cell receptor, KIR2DS1, is associated with susceptibility to psoriasis vulgaris. Hum Immunol 2004, 65:758-766.
13. Gustincich S., Manfioletti G., Del Sal G., Schneider C., Carninci P. A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques 1991, 11(298-300):302.
14. Łuszczek W., Majorczyk E., Nowak I., Pawlik A., Jasek M., Wiśniewski A. Inhibitory and activatory KIR gene frequencies in Polish population. Int J Immunogenet 2006, 33:167-170.
15. Vilches C., Castano J., Gómez-Lozano N., Estefania E. Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. Tissue Antigens 2007, 70:415-422.
16. Frohn C., Schlenke P., Ebel B., Dannenberg C., Bein G., Kirchner H. DNA typing for natural killer cell inhibiting HLA-Cw groups NK1 and NK2 by PCR-SSP. J Immunol Methods 1998, 218(1-2):155-160.
17. Lemeshow S., Hosmer D.W. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982, 115(1):92-106.
18. International HIV Controllers Study The major determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010, 330:1551-1557.
19. Robson N.C., McAlpine T., Knights A.J., Schnurr M., Shin A., Chen W. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery. Blood 2010, 116:218-225.
20. Elliott J.M., Yokoyama W.M. Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol 2011, 32:364-372.
21. dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010, 116:3853-3864.
22. Schönberg K., Sribar M., Enczmann J., Fischer J.C., Uhrberg M. Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood 2011, 117:98-107.
23. http://www.allelefrequencies.net/kir6006a.asp?kir_positives=on&kir_allele=2DL1.
24. Maat W., van der Slik A.R., Verhoeven D.H., Alizadeh B.Z., Ly L.V., Verduijn W. Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients. Invest Ophthalmol Vis Sci 2009, 50(6):2888-2895.
25. Middleton D., Diler A.S., Meenagh A., Sleator C., Gourraud P.A. Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. Tissue Antigens 2009, 73(6):553-560.
26. Boyton R.J., Altmann D.M. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol 2007, 149(1):1-8.
27. Purdy A.K., Campbell K.S. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther 2009, 8(23):2211-2220.